The Conundrum of Rash in Management of EGFR Inhibitors

Faculty: Roy S. Herbst, MD, PhD | Mario Lacouture, MD | Roman Perez-Soler, MD | Sandy Kurtin, RN, MS, AOCN
CME / CE credit hour: 1.0
New therapies targeting the epidermal growth factor receptor (EGFR) have been used in the treatment of a variety of cancers. Although generally well tolerated, EGFR inhibitors are associated with the development of dermatologic reactions (e.g., papulopustular rash, xerosis, pruritus, periungual inflammation, and alopecia) in most patients. At present, little is known about the etiology of these reactions, and no evidence-based management guidelines have been set forth in the dermatologic literature. 

reviewed by MASCC

 Real Issues In Treating Lung Cancer Patients

- CME activity offers up to 3 AMA PRA Category 1 CreditsTM
- For oncologists and other medical professionals who work with lung cancer
patients.
- Addresses systemic chemotherapy, chemotherapy support, bone
complications, depression and anxiety, and palliative and hospice care
referral issues.
- To receive "real time" CME credit, click on title above, read the
monograph, register and complete a self-assessment test and evaluation
online.

Reviewed by MASCC